Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Cisplatin for Stage IV Lung Cancer
NCT07495098Phase 1Not yet recruiting
- Sponsor
- The University of Vermont
- Start
- Jul 2026
- Primary completion
- Jul 2030
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of cisplatin in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by The University of Vermont. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07495098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495098.